TIAA Trust National Association Reduces Position in Humana Inc. (NYSE:HUM)

TIAA Trust National Association trimmed its holdings in Humana Inc. (NYSE:HUM) by 10.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,144 shares of the insurance provider’s stock after selling 128 shares during the quarter. TIAA Trust National Association’s holdings in Humana were worth $290,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of HUM. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Humana during the third quarter valued at $404,000. Glenmede Trust Co. NA boosted its position in Humana by 7.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 25,718 shares of the insurance provider’s stock valued at $8,146,000 after buying an additional 1,813 shares during the period. CreativeOne Wealth LLC bought a new position in Humana in the 3rd quarter worth about $208,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Humana by 1.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 856,954 shares of the insurance provider’s stock worth $271,432,000 after acquiring an additional 9,100 shares during the period. Finally, Public Sector Pension Investment Board raised its stake in shares of Humana by 13.0% during the third quarter. Public Sector Pension Investment Board now owns 5,222 shares of the insurance provider’s stock valued at $1,654,000 after acquiring an additional 600 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Stock Performance

HUM opened at $263.95 on Friday. The company has a market cap of $31.86 billion, a P/E ratio of 26.53, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm’s 50-day moving average price is $270.14 and its 200-day moving average price is $274.38. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.34%. Humana’s payout ratio is presently 35.58%.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.37% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. StockNews.com cut Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, March 18th. Barclays increased their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Eighteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.